$CABA
Cabaletta Bio, Inc.

2022 Q4 Form 10-Q Financial Statement

#000095017022024168 Filed on November 10, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3 2021 Q3
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.902M $3.562M $3.394M
YoY Change -1.81% 4.95% 22.53%
% of Gross Profit
Research & Development $12.40M $8.216M $8.169M
YoY Change 25.01% 0.58% 44.58%
% of Gross Profit
Depreciation & Amortization $358.0K $363.0K $221.0K
YoY Change 52.99% 64.25% 145.56%
% of Gross Profit
Operating Expenses $16.30M $11.78M $11.56M
YoY Change 17.34% 1.86% 37.33%
Operating Profit -$11.78M -$11.56M
YoY Change 1.86%
Interest Expense $610.0K $351.0K $3.000K
YoY Change 12100.0% 11600.0% -85.0%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$15.69M -$11.43M -$11.56M
YoY Change 12.99% -1.15% 37.78%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$15.69M -$11.43M -$11.56M
YoY Change 12.99% -1.15% 37.73%
Net Earnings / Revenue
Basic Earnings Per Share -$0.39 -$0.45
Diluted Earnings Per Share -$0.52 -$0.39 -$536.8K
COMMON SHARES
Basic Shares Outstanding 29.01M 29.01M 24.97M
Diluted Shares Outstanding

Balance Sheet

Concept 2022 Q4 2022 Q3 2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $106.5M $85.90M $119.3M
YoY Change -12.83% -27.98% 2.19%
Cash & Equivalents $81.61M $61.16M $118.3M
Short-Term Investments $24.94M $24.73M $1.000M
Other Short-Term Assets $2.287M $2.280M $1.592M
YoY Change -1.38% 43.22% -36.32%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $108.8M $88.18M $120.9M
YoY Change -12.61% -27.04% 1.39%
LONG-TERM ASSETS
Property, Plant & Equipment $2.578M $2.811M $1.462M
YoY Change 79.28% 92.27% 46.2%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $565.0K $689.0K $324.0K
YoY Change 58.26% 112.65% 62.0%
Total Long-Term Assets $8.134M $3.500M $1.786M
YoY Change 353.15% 95.97% -31.31%
TOTAL ASSETS
Total Short-Term Assets $108.8M $88.18M $120.9M
Total Long-Term Assets $8.134M $3.500M $1.786M
Total Assets $117.0M $91.68M $122.6M
YoY Change -7.42% -25.25% 0.69%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.463M $1.333M $1.707M
YoY Change 5.57% -21.91% 70.7%
Accrued Expenses $5.694M $2.268M $1.710M
YoY Change 91.27% 32.63% 14.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $9.489M $5.801M $6.023M
YoY Change 13.23% -3.69% 40.07%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $2.959M
YoY Change
Total Long-Term Liabilities $2.959M $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $9.489M $5.801M $6.023M
Total Long-Term Liabilities $2.959M $0.00 $0.00
Total Liabilities $12.45M $5.801M $6.023M
YoY Change 48.54% -3.69% 40.07%
SHAREHOLDERS EQUITY
Retained Earnings -$165.6M -$149.9M -$98.70M
YoY Change 47.05% 51.85%
Common Stock $270.1M $236.0M
YoY Change 17.17%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $104.5M $85.87M $116.6M
YoY Change
Total Liabilities & Shareholders Equity $117.0M $91.68M $122.6M
YoY Change -7.42% -25.25% 0.69%

Cashflow Statement

Concept 2022 Q4 2022 Q3 2021 Q3
OPERATING ACTIVITIES
Net Income -$15.69M -$11.43M -$11.56M
YoY Change 12.99% -1.15% 37.73%
Depreciation, Depletion And Amortization $358.0K $363.0K $221.0K
YoY Change 52.99% 64.25% 145.56%
Cash From Operating Activities -$12.13M -$9.914M -$8.344M
YoY Change 15.37% 18.82% 65.88%
INVESTING ACTIVITIES
Capital Expenditures $316.0K -$1.092M -$530.0K
YoY Change -309.27% 106.04% 231.25%
Acquisitions
YoY Change
Other Investing Activities $0.00 $25.00M $2.300M
YoY Change -100.0% 986.96% 40.24%
Cash From Investing Activities -$316.0K $23.91M $1.770M
YoY Change -137.22% 1250.73% 20.41%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 32.89M 0.000 25.34M
YoY Change 141.35% -100.0% 19391.54%
NET CHANGE
Cash From Operating Activities -12.13M -9.914M -8.344M
Cash From Investing Activities -316.0K 23.91M 1.770M
Cash From Financing Activities 32.89M 0.000 25.34M
Net Change In Cash 20.44M 13.99M 18.77M
YoY Change 416.0% -25.42% -647.08%
FREE CASH FLOW
Cash From Operating Activities -$12.13M -$9.914M -$8.344M
Capital Expenditures $316.0K -$1.092M -$530.0K
Free Cash Flow -$12.45M -$8.822M -$7.814M
YoY Change 20.1% 12.9% 60.45%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Address State Or Province
EntityAddressStateOrProvince
PA
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
19104
dei Entity Address City Or Town
EntityAddressCityOrTown
Philadelphia
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
CY2022Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
dei Entity Central Index Key
EntityCentralIndexKey
0001759138
dei Amendment Flag
AmendmentFlag
false
CY2022Q3 us-gaap Preferred Stock Value
PreferredStockValue
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39103
dei Entity Registrant Name
EntityRegistrantName
CABALETTA BIO, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
82-1685768
dei Entity Address Address Line1
EntityAddressAddressLine1
2929 Arch Street
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 600
dei City Area Code
CityAreaCode
267
dei Local Phone Number
LocalPhoneNumber
759-3100
dei Security12b Title
Security12bTitle
Common Stock, par value $0.00001 per share
dei Trading Symbol
TradingSymbol
CABA
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
29013995
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
61163000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
122222000
CY2022Q3 us-gaap Short Term Investments
ShortTermInvestments
24732000
CY2022Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2280000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2319000
CY2022Q3 us-gaap Assets Current
AssetsCurrent
88175000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
124541000
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2811000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1438000
CY2022Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
689000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
357000
CY2022Q3 us-gaap Assets
Assets
91675000
CY2021Q4 us-gaap Assets
Assets
126336000
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1333000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2333000
CY2022Q3 caba Accrued Liabilities And Other Liabilities Current
AccruedLiabilitiesAndOtherLiabilitiesCurrent
4468000
CY2021Q4 caba Accrued Liabilities And Other Liabilities Current
AccruedLiabilitiesAndOtherLiabilitiesCurrent
6047000
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
5801000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
8380000
CY2022Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
29013995
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
29013995
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
28927129
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
28927129
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
0
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
0
CY2022Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
235953000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
230543000
CY2022Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-209000
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-149870000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-112587000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
85874000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
117956000
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
91675000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
126336000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8216000
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8169000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
26900000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
22575000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3562000
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3394000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10937000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9845000
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
11778000
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
11563000
us-gaap Operating Expenses
OperatingExpenses
37837000
us-gaap Operating Expenses
OperatingExpenses
32420000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-11778000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-11563000
us-gaap Operating Income Loss
OperatingIncomeLoss
-37837000
us-gaap Operating Income Loss
OperatingIncomeLoss
-32420000
CY2022Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
351000
CY2021Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
3000
us-gaap Investment Income Interest
InvestmentIncomeInterest
554000
us-gaap Investment Income Interest
InvestmentIncomeInterest
19000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-11427000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-11560000
us-gaap Net Income Loss
NetIncomeLoss
-37283000
us-gaap Net Income Loss
NetIncomeLoss
-32401000
CY2022Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
40000
CY2021Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-1000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-209000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-6000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-11387000
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-11561000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-37492000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-32407000
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.39
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.39
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.45
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.45
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.29
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.29
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.31
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.31
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
109544000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1310000
CY2021Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
2165000
CY2021Q1 us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
-3000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-9702000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
103314000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1385000
CY2021Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
7665000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
60000
CY2021Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
46000
CY2021Q2 us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
-2000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-11139000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
101329000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1508000
CY2021Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
24880000
CY2021Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
459000
CY2021Q3 us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
-1000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-11560000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
116615000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
117956000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1811000
CY2022Q1 us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
-152000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
51000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-12946000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
106720000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1777000
CY2022Q2 us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
-97000
CY2022Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
40000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-12910000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
95530000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1731000
CY2022Q3 us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
40000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-11427000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
85874000
us-gaap Profit Loss
ProfitLoss
-37283000
us-gaap Profit Loss
ProfitLoss
-32401000
us-gaap Share Based Compensation
ShareBasedCompensation
5319000
us-gaap Share Based Compensation
ShareBasedCompensation
4203000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
177000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-62000
us-gaap Depreciation
Depreciation
820000
us-gaap Depreciation
Depreciation
499000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-39000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-3280000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
332000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
25000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1055000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
409000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-1580000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
379000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-34249000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-23594000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2137000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1015000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
49764000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
25000000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
6165000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-26901000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
5150000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
34710000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
51000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
519000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
40000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
46000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
91000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
35275000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-61059000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
16831000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
122222000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
101429000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
61163000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
118260000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
191000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
76000
CY2022Q3 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
85895000
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-149870000
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of expenses during the reporting period. Significant estimates and assumptions made in the accompanying financial statements include, but are not limited to, the fair value of stock-based compensation, the valuation allowance on the Company’s deferred tax assets and certain accruals. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could differ from those estimates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y3M18D
CY2021Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
0
CY2022Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
86104000
CY2022Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
209000
CY2022Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
85895000
CY2022Q3 caba Accrued Research And Development Services Current
AccruedResearchAndDevelopmentServicesCurrent
1880000
CY2021Q4 caba Accrued Research And Development Services Current
AccruedResearchAndDevelopmentServicesCurrent
2836000
CY2022Q3 caba Accrued General And Administrative Services Current
AccruedGeneralAndAdministrativeServicesCurrent
249000
CY2021Q4 caba Accrued General And Administrative Services Current
AccruedGeneralAndAdministrativeServicesCurrent
180000
CY2022Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2268000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2977000
CY2022Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
71000
CY2021Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
54000
CY2022Q3 caba Accrued Liabilities And Other Liabilities Current
AccruedLiabilitiesAndOtherLiabilitiesCurrent
4468000
CY2021Q4 caba Accrued Liabilities And Other Liabilities Current
AccruedLiabilitiesAndOtherLiabilitiesCurrent
6047000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
500000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Rolling Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths
2279000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due In Rolling Year Two
LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo
2286000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due In Rolling Year Three
LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree
1146000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
6211000
CY2019Q4 us-gaap Common Stock Conversion Features
CommonStockConversionFeatures
Each share of the Company’s non-voting common stock may be converted at any time into one share of common stock at the option of its holder by providing 61 days written notice to the Company
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0147
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0336
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0063
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0155
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.79
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.83
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.79
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.81
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2022Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
13403000
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022Q3 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6084284
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4041091

Files In Submission

Name View Source Status
0000950170-22-024168-index-headers.html Edgar Link pending
0000950170-22-024168-index.html Edgar Link pending
0000950170-22-024168.txt Edgar Link pending
0000950170-22-024168-xbrl.zip Edgar Link pending
caba-20220930.htm Edgar Link pending
caba-20220930.xsd Edgar Link pending
caba-ex10_1.htm Edgar Link pending
caba-ex31_1.htm Edgar Link pending
caba-ex31_2.htm Edgar Link pending
caba-ex32_1.htm Edgar Link pending
caba-ex32_2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
caba-20220930_def.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
caba-20220930_pre.xml Edgar Link unprocessable
caba-20220930_cal.xml Edgar Link unprocessable
caba-20220930_lab.xml Edgar Link unprocessable
caba-20220930_htm.xml Edgar Link completed
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending